106 filings
6-K
ASLN
ASLAN Pharmaceuticals Ltd
14 Jun 24
Aslan Pharmaceuticals Announces Plan to Implement Ads Ratio Change
4:46pm
6-K
ASLN
ASLAN Pharmaceuticals Ltd
31 May 24
Current report (foreign)
4:25pm
6-K
ASLN
ASLAN Pharmaceuticals Ltd
9 May 24
Aslan Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:10am
6-K
ASLN
ASLAN Pharmaceuticals Ltd
7 May 24
Current report (foreign)
7:41am
6-K
ASLN
ASLAN Pharmaceuticals Ltd
22 Apr 24
Aslan Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab In Dupilumab-experienced Atopic Dermatitis Patients
8:29am
6-K
0uwx76 1m
19 Apr 24
Aslan Pharmaceuticals Announces Receipt of Nasdaq Notice
5:01pm
6-K
jrshl8 czc
12 Apr 24
Amendment No. 2 to the Open Market Sale Agreementsm
8:10am
6-K
a4bj9q4 v6k1
12 Apr 24
Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
6:05am
6-K
9t01z3s3izdc
13 Mar 24
Aslan Pharmaceuticals Announces $5 Million Registered Direct Offering
7:27am
6-K
p600lhna gw4n8jecon
11 Mar 24
ASLAN PHARMACEUTICALS PROVIDES TREK-DX STUDY UPDATE AND HIGHLIGHTS potENTIAL of EBLASAKIMAB in DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS
8:03am
6-K
suqyc
24 Jan 24
Current report (foreign)
7:52am
6-K
giarksfzk8bfqkygxls
8 Jan 24
Aslan Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
7:02am
6-K
p5ysn3j6aq15c01
22 Dec 23
Current report (foreign)
4:24pm
6-K
fafe vxlagz8
8 Dec 23
Current report (foreign)
4:42pm
6-K
1yz1qyx
27 Oct 23
Aslan Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8:14am
6-K
30yb3q
24 Oct 23
Aslan Pharmaceuticals to Co-host Kol Panel Discussion Today on Changes In the Clinical Trial and Treatment Landscape for Atopic Dermatitis
8:32am
6-K
x258ab
16 Oct 23
Current report (foreign)
6:08am
6-K/A
0xx2bu agoh2un3w
18 Aug 23
Current report (foreign) (amended)
7:33am
6-K
mnc8z
11 Aug 23
Aslan Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
zi25gq28f5ffv
20 Jul 23
Current report (foreign)
7:55am